Zobrazeno 1 - 10
of 137
pro vyhledávání: '"Lars Kjeldsen"'
Autor:
Nigel H. Russell, Robert K. Hills, Abin Thomas, Ian Thomas, Lars Kjeldsen, Mike Dennis, Charles Craddock, Sylvie Freeman, Richard E. Clark, Alan K. Burnett
Publikováno v:
Haematologica, Vol 107, Iss 7 (2021)
Reduced intensity conditioning (RIC) transplantation is increasingly offered to older patients with acute myeloblastic leukemia. We have previously shown that a RIC allograft, particularly from a sibling donor, is beneficial in intermediate-risk pati
Externí odkaz:
https://doaj.org/article/ea905c516b5547eebbeabeafe8d82f35
Publikováno v:
Annals of Intensive Care, Vol 7, Iss 1, Pp 1-11 (2017)
Abstract Background Patients with malignant haematological disease and especially those who require intensive care have an increased risk of bleeding and thrombosis, but none of these data were obtained in ICU patients only. We assessed the incidence
Externí odkaz:
https://doaj.org/article/871b942ddd05499c9591369fc3dec518
Autor:
Alan K Burnett, Emma Das Gupta, Steve Knapper, Asim Khwaja, Marion Sweeney, Lars Kjeldsen, Timothy Hawkins, Sophie E Betteridge, Paul Cahalin, Richard E Clark, Robert K Hills, Nigel H Russell
Publikováno v:
Haematologica, Vol 103, Iss 10 (2018)
As part of the UK NCRI AML17 trial, adult patients with acute myeloid leukemia in remission could be randomized to receive the mammalian target of rapamycin inhibitor everolimus, sequentially with post-induction chemotherapy. Three hundred and thirty
Externí odkaz:
https://doaj.org/article/137ea70794c64954ac9332b82770f208
Autor:
Paul Ferguson, Robert K. Hills, Angela Grech, Sophie Betteridge, Lars Kjeldsen, Michael Dennis, Paresh Vyas, Anthony H. Goldstone, Donald Milligan, Richard E. Clark, Nigel H. Russell, Charles Craddock
Publikováno v:
Haematologica, Vol 101, Iss 11 (2016)
Up to 30% of adults with acute myeloid leukemia fail to achieve a complete remission after induction chemotherapy - termed primary refractory acute myeloid leukemia. There is no universally agreed definition of primary refractory disease, nor have th
Externí odkaz:
https://doaj.org/article/f772d011430040108f48560b445e89d7
Autor:
Mary Jarden, Tom Møller, Karl Bang Christensen, Lars Kjeldsen, Henrik Sverre Birgens, Lis Adamsen
Publikováno v:
Haematologica, Vol 101, Iss 7 (2016)
Externí odkaz:
https://doaj.org/article/5a07bdc4e7374a13a34c775c5d09941b
Autor:
Lars Möllgård, Leonie Saft, Marianne Bach Treppendahl, Ingunn Dybedal, Jan Maxwell Nørgaard, Jan Astermark, Elisabeth Ejerblad, Hege Garelius, Inge Høgh Dufva, Monika Jansson, Martin Jädersten, Lars Kjeldsen, Olle Linder, Lars Nilsson, Hanne Vestergaard, Anna Porwit, Kirsten Grønbæk, Eva Hellström Lindberg
Publikováno v:
Haematologica, Vol 96, Iss 7 (2011)
Background Patients with chromosome 5 abnormalities and high-risk myelodysplastic syndromes or acute myeloid leukemia have a poor outcome. We hypothesized that increasing doses of lenalidomide may benefit this group of patients by inhibiting the tumo
Externí odkaz:
https://doaj.org/article/141d2a56ccab4820add460edcc817c01
Publikováno v:
Husted Nielsen, I, Piil, K, Tolver, A, Grønbæk, K, Kjeldsen, L & Jarden, M 2022, ' Family caregiver ambassador support for caregivers of patients with newly diagnosed hematological cancer : a feasibility study ', Supportive Care in Cancer, vol. 30, no. 8, pp. 6923-6935 . https://doi.org/10.1007/s00520-022-07089-0
Purpose: This study investigated the feasibility of a one-on-one peer support intervention in family caregivers of newly diagnosed patients with a hematological cancer during initial treatment. Methods: The study was a one-arm feasibility study inclu
Autor:
Ian Thomas, Charles Craddock, Michael Dennis, Richard E. Clark, Sylvie D. Freeman, Lars Kjeldsen, Abin Thomas, Nigel H. Russell, Alan Kenneth Burnett, Robert Kerrin Hills
Publikováno v:
Haematologica. 107:1518-1527
Reduced intensity conditioning (RIC) transplantation is increasingly offered to older patients with acute myeloblastic leukemia. We have previously shown that a RIC allograft, particularly from a sibling donor, is beneficial in intermediate-risk pati
Autor:
Ian Thomas, Richard E. Clark, Jonathan Kell, Lars Kjeldsen, Nigel H. Russell, Brian J. P. Huntly, Robert Kerrin Hills, Alan Kenneth Burnett, Stephen Knapper, Mark Drummond, Sylvie D. Freeman, Mary Frances McMullin, Ruth Spearing
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Burnett, A K, Russell, N H, Hills, R K, Knapper, S, Freeman, S, Huntly, B, Clark, R E, Thomas, I F, Kjeldsen, L, McMullin, M F, Drummond, M, Kell, J & Spearing, R 2020, ' Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses ', Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology, pp. JCO2001170 . https://doi.org/10.1200/JCO.20.01170
Burnett, A K, Russell, N H, Hills, R K, Knapper, S, Freeman, S, Huntly, B, Clark, R E, Thomas, I F, Kjeldsen, L, McMullin, M F, Drummond, M, Kell, J & Spearing, R 2020, ' Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses ', Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology, pp. JCO2001170 . https://doi.org/10.1200/JCO.20.01170
PURPOSE The optimum number of treatment courses for younger patients with acute myeloid leukemia (AML) is uncertain. The United Kingdom National Cancer Research Institute AML17 trial randomly assigned patients who were not high risk to a total of thr
Autor:
Nigel H. Russell, Robert K. Hills, Lars Kjeldsen, Richard E. Clark, Sahra Ali, Paul Cahalin, Ian F. Thomas, Alan K. Burnett
The prognosis for younger patients with relapsed acute myeloid leukaemia (AML) is generally dismal. Allogeneic stem cell transplantation is the preferred therapy for these patients. As part of the UK NCRI AML17 trial, daunorubicin/clofarabine (DClo)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1f716c1ce573d298177610e141eff84